SUMMARY Vital to the success of the Lung Cancer P01, the overall goal of the Administrative Core is to provide leadership and coordination of all scientific activities, as well as fiscal management and general administrative activities in order to maximize the integrated performance of the Emory University Lung Cancer P01. The Administrative Core will be led by Drs. Haian Fu, Suresh Ramalingam and Adam Marcus, whose varied experience and expertise in the successful and productive management of individual and large multi- disciplinary research programs combines the perspectives of a basic research cancer pharmacologist with a translational clinical investigator and an expert in LKB1 biology in order to streamline and ensure high-quality decision-making for the P01. The Administrative Core will provide three distinct specific functions: (1) administration (2) coordination (3) monitoring and implementation. Administrative functions will include oversight of all Project and Core activities, fiscal oversight, provision of the necessary resources, acquisition and allocation of institutional support, preparation of annual progress reports and other documents. Coordination functions will include planning and scheduling of monthly program meetings and regular advisory board meetings, engagement of advisory board members including patient advocates, coordination of interactions between Projects, Cores and between the P01 and the Cancer Center, communication and consultation with NCI project officer and staff, organization of P01-sponsored lectures and symposia. Monitoring and implementation will include regular tracking and evaluation of research progress and data quality for all projects and cores, implementation of advisors’ recommendations, remediation of under-performing projects, and assuring compliance with all governmental, NCI, and local regulations and requirements. Guided by the P01 Executive Committee, comprised of Program, Project and Core leaders, as well as engaged advisory boards, the Administrative Core will facilitate intra-programmatic collaborations and integration of the projects and cores to result in a unified multidisciplinary approach focused on exploiting our improved understanding of LKB1-associated immunotherapy resistance in lung adenocarcinoma and translating these studies into current and future therapeutic opportunities.